基金项目:广东省中医药局科研项目(20201252);广东省医学科学技术研究基金项目(A2020188);广州市科技计划项目(202002030175);华南理工大学中央高校基本科研业务费专项资金资助项目(D2200420)通信作者:钟伟杰,E-mail:eyweijiezhong@scut.edu.cn含达雷妥尤单抗方案巩固和维持治疗高龄高危初治多发性骨髓瘤1例并文献复习钟伟杰朱志刚广州市第一人民医院老年病科血液肿瘤科(广州510180)【摘要】目的观察达雷妥尤单抗联合来那度胺及地塞米松(DRd)方案巩固治疗序贯达雷妥尤单抗和来那度胺两药维持治疗1例高龄高危初治多发性骨髓瘤患者的疗效、生存时间和不良反应。方法回顾分析广州市第一人民医院老年病科血液肿瘤科2019年3月收治的1例高龄高危初治多发性骨髓瘤患者的临床资料,并复习相关最新文献。结果患者应用伊沙佐米、来那度胺和地塞米松方案诱导治疗13疗程后只达到部分缓解的疗效,未能进一步缓解,且不良反应多且严重,后改为DRd方案巩固治疗2疗程后,达到完全缓解,继续使用达雷妥尤单抗联合来那度胺两药维持治疗,不良反应少,至随访结束总生存期和无进展生存期均为35个月。结论含达雷妥尤单抗方案巩固和维持治疗可能会改善高龄高危初治多发性骨髓瘤患者的预后,延长生存时间,耐受性好。【关键词】达雷妥尤单抗;多发性骨髓瘤;高龄;高危DOI:10.3969/j.issn.1000-8535.2023.02.014Consolidationandmaintenancetherapywithdaratumumabinelderlypatientwithhigh-risknewlydiagnosedmultiplemyeloma:AcasereportandliteraturereviewZHONGWeijie,ZHUZhigangDepartmentofGeriatrics,Hematology&OncologyWard,GuangzhouFirstPeople'sHospital,Guangzhou510180,China【Abstract】ObjectiveToobservetheefficacy,survivaltimeandadversereactionsofdaratumumabcombinedwithlenalidomideanddexamethasone(DRd)intheconsolidationtreatmentofsequentialdaratumumabandlenalidomidemainte-nancetreatmentofanelderlypatientwithhigh-risknewlydiagnosedmultiplemyeloma.MethodsTheclinicaldataoftheelderlypatientwithnewlydiagnosedmultiplemyelomatreatedintheDepartmentofGeriatrics,Hematology&OncologyWard,GuangzhouFirstPeople'sHospitalinMarch2019wereretrospectivelyanalyzed,andtherelevantlatestliteratureswerereviewed.ResultsAfter13coursesofinductiontreatmentwithisazomib,lenalidomideanddexamethasone,itonlyachievedpartialremission,butfailedtof...
